

Lab on a Chip

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.


You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Clog-free Cell Filtration Using Resettable Cell Traps

William J. Beattie, Xi Qin, Lin Wang, and Hongshen Ma

A microfluidic cell separation mechanism created using constrictions with adjustable size that can selectively capture and release cells and thereby enabling high throughput size and deformability based cell separation without clogging.



Clog-free Cell Filtration Using Resettable Cell Traps

William Beattie^a, Xi Qin^a, Lin Wang^a, and Hongshen Ma^{a,b,c}

^a Department of Mechanical Engineering, University of British Columbia, 2054-6250 Applied Science Lane, Vancouver, BC, Canada V6T 1Z4

^b Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada

^c Department of Urologic Science, University of British Columbia, Vancouver, BC, Canada

Abstract

The separation of cells by filtration through microstructured constrictions is limited by clogging and adsorption, which reduce selectivity and prevent the extraction of separated cells. To address this key challenge, we developed a mechanism for simply and reliably adjusting the cross-section of a microfluidic channel to selectively capture cells based on a combination of size and deformability. After a brief holding period, trapped cells can then be released back into flow, and if necessary, extracted for subsequent analysis. Periodically clearing filter constrictions of separated cells greatly improves selectivity and throughput, and minimizes adsorption of cells to the filter microstructure. This mechanism is capable of discriminating cell-sized polystyrene microspheres with $<1\ \mu\text{m}$ resolution. Rare cancer cells doped into leukocytes can be enriched $\sim 1800\times$ with $\sim 90\%$ yield despite a significant overlap in size between these cell types. An important characteristic of this process is that contaminant leukocytes are captured by non-specific adsorption and not mechanical constraint, enabling repeated filtration to improve performance. The throughput of this mechanism is 900,000 cells per hour for 32 multiplexed microchannels, or $\sim 1200,000\ \text{cells}/\text{cm}^2\cdot\text{hour}$ on a per area basis, which exceed existing micropore filtration mechanisms by a factor of 20.

Introduction

The separation of cells based on their physical properties is important in many biological and biomedical applications where known physical differences can be used to distinguish target and background cells. For example, circulating tumor cells (CTCs) are thought to be distinguishable from peripheral blood cells based on physical characteristics [1] [2], while biochemical cell surface markers used to isolate CTCs in current processes are thought to be unreliable [3] [4]. Furthermore, these cells have been observed to arrest in the microvasculature because of their larger size and limited deformability [5], suggesting that

30 there may be situations where separation based on physical properties may be an appropriate method
31 for capturing these cells.

32 Current methods in label-free cell separation can be classified as flow-based fractionation or micropore
33 filtration. Flow-based fractionation methods function by laterally displacing cells across streamlines in a
34 flow field using mechanisms such as size exclusion near obstacles [8] [9] [10], inertial forces [11] [12],
35 and attraction using an electric [13] [14] [15] [16] or gravitational fields [17]. These methods typically
36 discriminate cells based on size, density, and electrical permittivity, which limit their specificity because
37 of the significant overlap in these parameters across different cell types. Micropore filtration relies on
38 the deformation of individual cells through micrometer scale constrictions to separate cells based on a
39 combination of size and deformability [18] [19] [20] [21]. This approach can often be more specific
40 because deformability varies considerably more than the parameters used in flow-based fractionation
41 across phenotypes [22] [23] [24]. The suitability of traditional membrane-based micropore filters for cell
42 separation, however, is limited by the ability to precisely control the force used to deform cells across
43 the filter microstructure, as well as the difficulties associated with the localization and extraction of the
44 separated cells for further processing [21].

45 Microfluidic technologies have the potential to overcome these limitations by using fluidic circuitry to
46 precisely control the force applied to each cell as it deforms through a constriction [22], as well as to
47 direct the flow of separated cells for subsequent processing. However, micropore filtration in
48 microfluidic devices is inherently low-throughput due to the planar nature of photolithographic
49 microfabrication. Specifically, since flow in a microfluidic device is constrained to a 2D plane, the micro-
50 scale constrictions used for separation can only be parallelized as a linear (1D) array. Additionally, cells
51 trapped in filter constrictions block subsequent cells from transiting through the constrictions, and the
52 buildup of these trapped cells alters the hydrodynamic resistance of the filter in an unpredictable way.
53 To ensure the reliable operation of filtration devices, the number of filter constrictions must vastly
54 outnumber the number of cells that are likely to be captured by the filter, which further limits
55 throughput per constriction.

56 A variety of microfluidic filtration devices have been developed that use pneumatic pressure to produce
57 an adjustable orifice, the earliest of which is the sieve valve [25]. Such devices have been employed to
58 separate microspheres from suspension [25] [26] [27] [28], chondrocytes from a suspension of digested
59 tissue [26], erythrocytes and plasma from whole blood [27], Filtration devices with adjustable geometry
60 are able to expand and purge captured cells from the filter area [27] [26] [28], and bacteria from

61 suspension [28], but are often limited to low flow rates and have not yet been demonstrated to
62 separate nucleated cell phenotypes. Separating nucleated phenotypes by filtration is considerably more
63 difficult than separating particles from suspension or non-nucleated cells from nucleated cells because
64 nucleated cells possess relatively similar physical properties. For example, the deformability of human
65 leukocytes differs from that of RT4 bladder cancer cells by a factor of 3-4 [22], while leukocytes and
66 erythrocytes differ in deformability by a factor of 20-40 [29].

67 To overcome these difficulties, we developed a microfluidic cell separation device using a resettable
68 microstructure with the ability to alternate between capturing target cells from a heterogeneous
69 mixture and releasing them back into the flow channel. The microstructure has sufficient precision to
70 resolve differences between nucleated cell phenotypes, and can capture and release cells repeatedly,
71 thus greatly expanding the throughput per constriction without compromising its selectivity.


72 **Design**

73 **Resettable Cell Trap Mechanism**

74 The structure of the resettable cell trap mechanism is shown in Figure 1A. Similar to conventional
75 membrane micro-valves [30], the cell trap consists of an upper flow channel for the sample that
76 overlaps a lower fluid-filled control channel. The two channels are separated by a thin diaphragm of
77 elastomeric material that can be deflected up or down by a pressure difference between the channels.
78 Unlike conventional micro-valves, the ceiling of the flow channel is a textured surface featuring a series
79 of recesses and a protruding center fin that functions as a mechanical stop to limit the travel of the
80 diaphragm (Figure 1B). The ability of a cell to transit through this microstructure is controlled by the
81 cross-sectional opening of the channel, which in turn is determined by the position of the diaphragm
82 (Figure 1C). Given sufficient pressure in the control layer, the diaphragm will deflect upward into
83 contact with the center fin of the flow channel, effectively bisecting the flow channel along its length.
84 The change in stiffness of the diaphragm can be approximated using the slender beam equation, under
85 which halving the diaphragm width increases its stiffness by a factor of 16 [31]. This abrupt change in
86 stiffness allows the membrane to assume a consistent shape once sufficient pressure has been applied
87 to create a contact with the center fin. Additional pressure only serves to fine-tune the size of the
88 opening. Recesses lining the ceiling of the flow channel serve as storage compartments for captured
89 cells to occupy so the cells do not completely occlude the channel, allowing other cells to pass without
90 clogging. Once the recesses fill up with captured cells, the channel is purged to empty the recesses.

91 While the diaphragm can be deflected continuously, there are two diaphragm positions useful for cell
 92 separation (Figure 1C). If the pressure difference across the diaphragm, herein known as the trapping
 93 pressure, is positive, the diaphragm is deflected upwards and contacts the center fin. This diaphragm
 94 position decreases the cross-sectional opening of the flow channel, configuring the trap in the
 95 constricted state. If the trapping pressure is negative, the diaphragm is deflected downwards and
 96 configures the trap in the relaxed state. The cell trap dimensions are designed such that the constricted
 97 state allows transit of background cells but is sufficiently small to arrest target cells, while the relaxed
 98 state readily allows the transit of all cells. In early experiments we observed target cells being captured
 99 at the front of the constriction, while background cells were captured throughout the constriction.
 100 Accordingly, we modified our design to minimize the length of the constricted region while still allowing
 101 the full inflation of the trap.

102



103


104 Figure 1. Structure and function of the resettable cell trap. A: Isometric cut-away view of the trap. The cell suspension flows
 105 through the upper channel. B: Profile of the mold for the flow channel as measured by a non-contact profilometer. C:
 106 Schematics of the cell trap in the constricted and relaxed states. Axial views show the deflection of the diaphragm floor under
 107 positive and negative trapping pressures. Section views show the effective channel height in both states. D: Top view of the
 108 hydrodynamic flow focuser upstream of the cell trap. Streamlines are superimposed in blue along with mock trajectories of
 109 large and small cells. Large cells will enter the cell trap area regardless of their initial lateral position upstream, while small cells
 110 may leak through the side and bypass the trap.

111 The cross-sectional shape of the constricted flow channel consists of two approximately rectangular
112 channels flanked by two small triangular side channels (Figure 1C). While the rectangular channels have
113 the recesses and controlled height that allow them to selectively capture target cells, the side channels
114 do not. The side channels exist merely because the diaphragm is bound at the sides of the channel; they
115 are not designed for separating cells. To prevent cells from entering these side channels, the
116 mechanism features hydrodynamic flow focusers upstream of the cell trap to help center incoming cells
117 (Figure 1D). These flow focusers, widely employed in microfluidic devices for processing cellular
118 samples [8] [9], bring cells near the outer edges of the flow channel into physical contact with the
119 channel walls, bumping the cells over to adjacent, more centered streamlines. In experiments, the
120 larger and more rigid cancer cells did not enter these side channels after passing through the flow
121 focuser.

122 A previous version of this mechanism was shown to impart different flow rates to different cell
123 phenotypes to potentially enable chromatographic cell separation [32]. In this paper, we demonstrate a
124 generalized method to use this mechanism for cell separation and subsequent extraction.

125 **Cell Separation Device**

126 The prototype cell separation device consists of 32 resettable cell traps in parallel and supporting
127 microfluidic elements including bifurcation microchannels to evenly distribute cells into the parallelized
128 cell traps [33]; inlet reservoirs for the cell sample and buffer; outlet reservoirs for the target cells and
129 waste cells; and micro-valves to route flow between these components (Figure 2A). A serpentine
130 channel between the cell traps and the outlet reservoirs provides a dominant hydrodynamic resistance
131 that facilitates controlling the diaphragm deflection. Specifically, the hydrodynamic resistance of this
132 element is more than 95% of the total device hydrodynamic resistance, such that the pressure drop
133 between the sample inlet and cell trap is negligible. Consequently, the trapping pressure can be read off
134 the pressure source gauges for the control and flow channel, thereby eliminating the need for on-chip
135 pressure sensors to regulate the deflection of the trap diaphragm.



136

137 Figure 2. A: Photograph of the separation device with the flow and control channels are filled with red and green food coloring
 138 respectively. During the separation process, sample from the inlet is initially bifurcated into 32 parallelized cell traps. The
 139 resettable cell traps, formed at the intersections of the wide green bar and the parallelized flow channels, capture target cells
 140 from the flow. The filtered sample is then directed into the collection and waste outlets through serpentine hydrodynamic
 141 resistors. B: Schematic operational cycle of the cell separation device. Fluid is delivered from the sample inlet (S), low pressure
 142 buffer (LPB) or high pressure buffer (HPB) inlet and direct towards the waste or collection reservoir. The operational cycle
 143 consists of filtration, purging, and collection.

144 Operational Cycle


145 The cell separation device operates on a repeating three-step cycle of filtration, purging, and collection
 146 (Figure 2B). In the filtration step, the sample is flowed through a constricted cell trap. Target cells
 147 accumulate at the constricted trap while background cells flow through the trap and into the waste
 148 reservoir. Eventually the trap's recesses will fill with target cells and flow through the channel will be
 149 obstructed. In experiments we observed a dramatic decrease in the ability of leukocytes to transit
 150 through a trap once it held more than four trapped cells. Accordingly, the duration of the filtration step
 151 was limited such that a volume of sample containing on average no more than two target cells per trap
 152 was filtered before purging. In a separation application with unknown target cell concentration, a
 153 conservative estimate would be required to determine the proper period of filtration. In the purging
 154 step, the trap remains constricted while buffer fluid flows through the trap towards the waste outlet to
 155 remove background cells from trap area. This step typically requires 5-10 seconds. Finally, in the
 156 collection step, the cell trap is opened and the released target cells flow into the collection reservoir.
 157 The release flow is approximately 3-4 times as fast as the flow in filtration and purging. The increased

158 speed produces greater shear forces that remove cells that may have adhered to the walls of the cell
159 traps [34]. A demonstration of the three-step cycle is provided in Video S1.

160 Results and Discussion

161 Separation Resolution

162 The ability of a particle to transit through the resettable cell trap is determined by the cross-sectional
163 opening between the diaphragm and the channel ceiling. The size of this opening can be adjusted using
164 the pressure difference between the flow and control channel to selectively capture particles greater
165 than a certain diameter. To characterize the separation resolution of this mechanism, we measured the
166 probability of capture for monodisperse microparticles as a function of the trapping pressure applied
167 between the flow and control channels. The tested microparticles (Bangs Labs, Fishers, IN) included
168 diameters of $6.4 \pm 0.3 \mu\text{m}$, $7.3 \pm 0.4 \mu\text{m}$, $9.5 \pm 0.3 \mu\text{m}$, and $10.1 \pm 0.4 \mu\text{m}$, selected to mimic the cross-
169 sectional width of deformed cells. The results of these experiments are shown in Figure 3. For each
170 particle size, the transition between no trapping and complete trapping occurs over 25-50 mbar of
171 pressure (shown as shaded regions). More importantly, there is little to no overlap in the transition
172 regions between different particle diameters, which indicate the resettable cell trap mechanism is
173 capable of resolving particles with $<1 \mu\text{m}$ resolution.



174

175 Figure 3. The probability of trapping microsphere as a function of pressure applied to the membrane. Smaller microspheres
176 require smaller channel openings to be captured, and therefore require greater trapping pressure than larger microspheres.
177 The range of trapping pressures for each particle size is shown as a colored block for each microsphere diameter, indicating the
178 minimal overlap between sizes.

179

180 Cell Separation and Optimization

181 We evaluated the ability to separate different cell types using the resettable cell trap mechanism by
182 separating cultured UM-UC13 bladder cancer cells (UC13) doped into a suspension of leukocytes. UC13


183 is a highly invasive phenotype that is EpCAM negative and therefore undetectable using established
184 affinity-capture based techniques such as the Veridex CellSearch® system [35]. As detailed in following
185 sections, we measured the physical properties of these cell types and found that UC13 are on average 5
186 μm greater in diameter and 5 to 10 times stiffer than leukocytes (Figure 5A & 5B). Importantly, these
187 phenotypes have overlapping size distributions but significantly different deformability. The overlap in
188 size distributions would therefore severely limit the effectiveness of separation mechanisms that
189 discriminate solely based on size.

190 To optimize the resettable cell trap mechanism for the selective capture UC13 cells, we first determined
191 the required membrane pressure by flowing UC13 cells through a single cell trap and adjusted the
192 trapping pressure until 95% of incident cells were captured. The optimal membrane pressure was found
193 to be 150 mbar. Next, we tested the separation of UC13 cells from leukocytes as a function of cell
194 concentration in the suspending media, and the relative concentration of leukocytes to UC13. The key
195 performance metrics are yield and enrichment. Yield refers to the fraction of target cells captured
196 relative to the total processed population. Enrichment refers to the enhancement of the population of
197 target cells relative to background cells in the outlet sample. We found the device to perform optimally
198 at a concentration of $\sim 2 \cdot 10^6$ leukocytes/ml (*i.e.* whole blood diluted 1:1 using PBS) and a UC13-leukocyte
199 doping ratio of $\sim 1:1000$.

200 To optimize the flow rate in the resettable cell trap structure, we tested the separation of UC13 cells
201 from leukocytes from 5 different donors as a function of flow rate. As shown in Figure 4A, at a flow rate
202 of < 4 mm/s, the resettable cell trap device was able to consistently obtain a yield of 88-96%, as
203 well as an enrichment value that increases with flow rate. For each data point, the measured result
204 shown is the average of triplicate experiments. A key factor limiting enrichment is the non-specific
205 adsorption of leukocytes to surfaces of the cell trap during the filtration phase. These adsorbed
206 leukocytes are released with the UC13 cells during the collection phase, thereby limiting the purity of
207 the output sample. As shown in Figure 4A, the enrichment of cancer cells relative to leukocytes
208 improves with increasing flow speed because of the increased shear forces reduces non-specific
209 adhesion of leukocytes [34]. The yield of UC13 cells is also not strongly dependent on flow rate at < 4
210 mm/s. When the flow rate is raised to 6 mm/s, however, the yield of UC13 cells drops to $\sim 70\%$.
211 Additionally, some trapped UC13 cells show signs of morphology change where the previously round
212 cells were observed to take on an elongated shape. Therefore, a flow rate of 4 mm/s is likely the
213 practical limit for the resettable cell trap device to retain a reasonable yield and prevent cell damage

214 from high shear force. These results further confirm that contaminant leukocytes are caught in the filter
 215 because of non-specific adsorption rather than mechanical constraint as in the case of cancer cells.

216 Based on an optimized flow rate of 4 mm/s, we then investigated the repeatability of device
 217 performance across multiple donors and within each donor. The measured enrichment showed
 218 significant variability across different donors ranging from ~170 to ~870 across five donors (Figure 4B).
 219 This observation is unsurprising since the properties of blood cells, specifically the non-specific
 220 adherence of leukocytes, can vary dramatically across humans, resulting in large variations in
 221 enrichment. When the device is tested using blood from the same donor, however, the measured
 222 enrichment and yield showed remarkable consistency (Figure 4C).



223
 224 Figure 4. Performance of the resettable cell trap mechanism. A: Enrichment and yield of UC13 cells doped into whole blood as a
 225 function of flow rate from 5 different donors. Each data point is the average of triplicate experiments on the same sample. B:
 226 Enrichment of yield of the resettable cell trap mechanism across different donors tested at a flow rate of 4 mm/s. For each
 227 donor, 3-5 tests were performed. C: Enrichment and yield measured for the same donor at a flow rate of 4 mm/s. D:
 228 Enrichment and yield results from 3X serial filtrations showing improved enrichment and minimal degradation in yield.

229

230


231 **Serial Enrichment**

232 One of the key results of our initial cell separation experiments is the realization that while cancer cells
233 are caught in the cell trap because of mechanical constraint, while leukocytes are caught because of
234 non-specific adsorption. This result suggests that repeatedly filtering the sample through multiple traps
235 could improve the level of target cell enrichment. To test this hypothesis, we processed a sample with a
236 starting concentration of $2 \cdot 10^6$ leukocytes/ml and UC13 cells doped into leukocytes at a ratio of 1:1,000.
237 After each pass through the device, the waste and collection outlets are imaged to count the number of
238 leukocytes and UC13 in each. We then pipetted the contents of the collection outlet back into the
239 sample inlet, emptied the waste reservoir, and repeated the separation process. As shown in Figure 4C,
240 while the first filtration step provides the greatest individual enrichment of the ratio of UC13 relative to
241 leukocytes, subsequent steps also provided substantial additional enrichment. The compounded effect
242 of all three steps is an enrichment of 1,845, with significant improvement compared to the single step
243 results described in the previous section. Importantly, loss of target cells occurred almost entirely in the
244 first step, which means that 90% of the target cells were retained even after three re-filtration steps.
245 These results validate the idea that leukocytes are captured in the microstructure because of non-
246 specific adhesion rather than mechanical constraint, and suggest that the level of enrichment could be
247 improved even further with more rounds of re-filtering. This capability is being integrated in future
248 versions of this device for rare cell separation applications such as the isolation of CTCs.

249 **Separation Based on Size and Deformability**

250 Cell separation techniques that discriminate based on size alone are attractive because to their
251 simplicity of operation and their high throughput. This approach, however, can be ineffective in
252 applications where target and background cells are of similar size. As a filtration based mechanism, the
253 resettable cell trap discriminates based on a combination of size and deformability and is likely to offer
254 superior performance in these applications. To investigate this enhanced discrimination, we
255 characterized the size and deformability of the target and background cell types (Figure 5A and 5B).
256 Given the overlapping size distributions of UC13 and leukocytes, separation based on size alone would
257 result in significantly heterogeneous separation result. For example, selecting all the cells in the mixture
258 greater than 20 μm in diameter would eliminate all leukocytes, but would also eliminate the vast
259 majority of UC13. Selecting all cells greater than 10 μm would ensure all UC13 were retained, but a
260 significant fraction of leukocytes would contaminate the output. Figure 5C shows the receiver-operator
261 curve of the maximum possible discrimination using size-only based separation. The additional

262 discrimination provided by deformability based separation enables the performance of resettable cell
 263 trap mechanism to greatly exceed this limit.




264

265 Figure 5. A: Size distribution of UC13 and leukocytes ($N=100$ for each population). There is substantial size overlap between the
 266 two phenotypes in the 11-15 μm range. B: Deformability of neutrophils, lymphocytes, and UC13 as measured by microfluidic
 267 micropipette aspiration [22]. C: Theoretical ROC for size based cell separation showing target cell yield and background cell
 268 depletion at different threshold diameters. The performance of the resettable cell trap mechanism shows significant
 269 improvement over the theoretical maximum for size-based separation.

270 Importance of the Anti-clogging Mechanism

271 The effectiveness of micropore filtration is limited by clogging, whereby the presence of cells captured
 272 by the filter alters the hydrodynamic resistance of the filter in an unpredictable manner and resulting in
 273 reduced selectivity. This problem can be mitigated by increasing the number of micropores such that the
 274 filtered cells occupy only a small fraction of the pores. However, doing so increases the device footprint
 275 and therefore reduces the throughput per unit area. The resettable cell trap mechanism avoids clogging
 276 problems altogether by periodically emptying the cell traps to enable sustained and reliable operation.
 277 To demonstrate the importance of this capability, Figure 6 shows the accumulation of cells in two traps:
 278 one is kept in the constricted state and never emptied, while the other is periodically purged and reset.
 279 UC13, captured primarily through mechanical constraint, accumulate at the first point of constriction
 280 near the front of the trap. Leukocytes, captured through a combination of adsorption and mechanical

281 constraint, begin to accumulate throughout the length of the trap's constriction. The non-resettable
 282 filter is fouled after just two minutes of operation. In contrast, periodically resetting the cell traps keeps
 283 the filter microstructure clear of cells, allowing the filtration process to continue indefinitely without
 284 decreasing the selectivity of the trap. Additionally, the ability to temporarily capture and release target
 285 cells reduces the amount of time these cells are pressed against the filter microstructures, thereby
 286 reducing adsorption and allowing target cells to be released and collected. The separated cells can then
 287 be analyzed by downstream microfluidic elements or extracted by pipetting. Other micropore filtration
 288 techniques do not accommodate the release of captured cells [20] [21], necessitating additional
 289 complexity for subsequent characterization of these cells.



290
 291 Figure 6. Comparison of a cell mixture flowing through a resetting trap and non-resetting trap mechanism. Each frame is a
 292 composite of bright field, blue fluorescence, and green fluorescence images. Target UC13 cells fluoresce green, background
 293 leukocytes fluoresce blue. The non-resetting trap functions properly for ~60 s, after which enough cells have accumulated in
 294 the cavities to clog the channel. The resetting trap is purged every 60 s and remains clean through multiple cycles.

295 **Throughput**

296 The prototype device contains 32 multiplexed channels that can process ~900,000 cells/hour. The
 297 overall throughput can be scaled by further parallelization with the only practical limit being the size of
 298 silicon wafer substrates used in photolithographic microfabrication. The total footprint for the 32-
 299 channel device is 4.5 cm² with only 0.77 cm² devoted to the cell traps and microchannels for
 300 multiplexing, equating to an area-normalized throughput of ~1200,000 cells/cm²·hour. Therefore,
 301 scaling the resettable cell trap mechanism to cover the usable area of a standard 100 mm silicon wafer
 302 would result in a throughput exceeding 4·10⁷ cells/hour. The throughput of the resettable cell trap
 303 mechanism compares favorably to other label-free cell separation techniques, exceeding the throughput
 304 of previous micropore filtration techniques by approximately a factor of 10 [9] [19] [38]. Ultra-fast cell
 305 separation methods with throughputs exceeding 10⁷ cells/cm²·hour can be achieved using inertial
 306 microfluidics, however these methods typically provide considerably lower enrichment [39] [40].

307 **Application to the Separation of Circulating Tumor Cells**

308 The separation of circulating tumor cells from peripheral whole blood is topic of significant current
 309 interest for physical cell separation technologies. The performance specifications required for this

310 application is extremely demanding in terms of both selectivity and throughput since the presence of as
311 few as 5 CTCs in 7.5 ml of whole blood has been established as a prognostic marker in several types
312 cancers [41]. Preprocessing steps such as CD45-based depletion of leukocytes can provide an initial CTC
313 enrichment of ~ 100 [42]. Combining CD45-based depletion and the ~ 1000 fold enrichment provided by
314 the resettable cell trap will result in a total enrichment on the order of 10^5 , which would leave ~ 100
315 leukocytes per ml of blood, a quantity sufficiently small to allow for individual examination of cells by
316 immunofluorescence to detect the CTCs. The throughput of the current 32-channel resettable cell trap
317 mechanism is 450,000 cells per hour, which would enable 7.5 ml of whole blood to be processed in less
318 than one hour following CD45 depletion. At this rate, identification and characterization would become
319 the primary bottle-neck of the CTC enumeration process. Additional parallelization of this mechanism
320 can potentially enable direct processing of whole blood.

321 **Conclusion**

322 We developed a resettable cell trap mechanism capable of simply and reliably adjusting the cross-
323 section of a microfluidic channel to selectively capture cells based on size and deformability, and then
324 subsequently release them for extraction and characterization. This capability addresses a long-standing
325 challenge in filtration based cell separation systems of how to prevent clogging and adsorption in order
326 to improve selectivity and enable the extraction of cells after separation. The resettable cell trap
327 mechanism avoids clogging and adsorption by periodically clearing the filtration microstructures to
328 allow sustained operation with high selectivity and throughput. Polystyrene spheres processed using this
329 mechanism could be separated with $<1 \mu\text{m}$ resolution. Rare UC13 cancer cells doped into a suspension
330 of leukocytes can be enriched $\sim 1800\text{X}$ with 90% yield despite the significant size overlap between the
331 two cell types. Interestingly, leukocyte contamination in this filtration process was found to result
332 primarily from non-specific adsorption, which can be mitigated using repeated filtration. The throughput
333 of our prototype device consisting of 32 parallelized microchannels is 900,000 cells/hour, or $\sim 1,200,000$
334 cells/cm²·hour on a per area basis, which exceed existing micropore filtration mechanisms by a factor of
335 20.

336 **Acknowledgements**

337 This work was supported by grants from Natural Science and Engineering Research Council of Canada,
338 Canadian Institutes of Health Research, Vancouver Prostate Centre's Translational Research Initiative for

339 Accelerated Discovery and Development, and Engineers-in-Scrubs training program at UBC.

340 **Materials and Methods**

341 **Sample Preparation**

342 Cell separation studies were performed using leukocytes and UM-UC13 bladder cancer cells. Whole
343 blood was drawn from healthy donors into 6 ml EDTA blood collection tubes. Whole blood is stained
344 with Hoechst 33342 (Invitrogen) and diluted with PBS to a concentration of 2 million leukocytes per ml.
345 UC13 bladder cancer cells were cultured in MEM solution with the addition of 10% (v/v) fetal bovine
346 serum, 1% L-glutamine, 1% MEM Non-Essential Amino Acids, 1% Sodium Pyruvate (Invitrogen), and 1%
347 Penicillin Streptomycin (Fisher Thermo Scientific, Waltham, MA), and incubated at 37°C in a humidified
348 environment with 5% CO₂. UC13 cancer cells were stained with calcein AM (Invitrogen) For separation
349 studies, UC13 were doped into diluted whole blood. The mixed sample processed in each cell separation
350 trial contained a minimum of 100 UC13. Each processed sample contained ~100,000 cells.

351 **Fabrication**

352 We fabricated the cell separation devices using standard multilayer soft lithography techniques [30].
353 Two master wafers were fabricated through photolithography to use as molds for the control and flow
354 channels. To produce the control wafer, SU-8 3025 photoresist (Microchem Corp., Newton, MA) was
355 spun on a silicon wafer at 3000 rpm for 30 seconds, exposed under a photomask (CAD/Art Services,
356 Bandon, OR), and developed following the photoresist manufacturer's protocol. The flow wafer,
357 comprising three separate feature heights, was produced by spinning and developing SU-8 3010, SU-8
358 3005, and SU-8 3025 for 30 seconds each at speeds of 2250 rpm, 3000 rpm, and 4000 rpm respectively.
359 Each layer was aligned to the previous using a Canon PLA-501F mask aligner (Canon USA, San Jose, CA)
360 before exposure. Rounded channels for microvalves were fabricated using SPR 220-7 photoresist (Rohm
361 and Haas, Midland, MI) spun at 625 rpm for 50 seconds, then exposed and developed following the
362 manufacturer's protocol.

363 Microfluidic devices for experiment were produced from the control and flow molds. To produce the
364 flow layer, PDMS (Sylgard 184, Dow Corning, Midland, MI) was poured onto the flow wafer at a 5:1 ratio
365 of base to crosslinker, degassed in a desiccator, and cured at 60°C for 1 hour. To produce the control
366 layer, PDMS was spun on the control wafer at a 20:1 ratio of base to crosslinker at 1250 rpm for 60s and
367 cured at 60°C for 1 hour. After curing the two layers were joined and left to diffusion bond overnight at
368 60°C. Fluidic ports and on-chip reservoirs were created using 0.5 mm OD and 6 mm OD punches,

369 respectively (Harris Unicore, Ted Pella Inc., Redding, CA). The punched devices were treated with
370 plasma (Harrick Plasma, Ithaca, NY) and bonded to a clean glass slide. Prior to use, device channels were
371 filled with a solution of 0.25% Pluronic F-127 and 5% BSA in MEM for surface passivation.

372 **Experimental Apparatus**

373 Fluids are loaded into the microfluidic device from 15 ml polypropylene reservoirs (BD Biosciences,
374 Mississauga, Canada) fitted with custom machined caps that allowed the reservoirs to be pressurized
375 from a pneumatic source. Fluids were delivered from these reservoirs via 0.5 mm ID flexible Tygon
376 tubing (Cole-Parmer, Montreal, Canada) which connected to the microfluidic device through a 23 gauge
377 stainless steel needle (New England Small Tube, Litchfield, NH). The pressure to actuate on-chip valves
378 was controlled by on-off solenoid valves and controlled using a MSP430 microprocessor (Texas
379 Instruments). A multi-channel variable pressure controller (MCFS-Flex, Fluigent, France) controlled the
380 pressure of the sample and buffer reservoirs.

381 **Experimental Characterization**

382 Counting Cells

383 The performance of our cell separation mechanism was characterized by the percentage of UC13 cells
384 captured by the cell traps (yield) and ratio of target cells to background cells in the output divided by the
385 same ratio in the input (enrichment). These values were measured by counting the number of UC13 and
386 leukocytes in the waste and collection reservoirs after separation. Individual cells were identified by
387 their stains. After each cell separation test, cells in the reservoirs were left undisturbed for 10-15
388 minutes to allow the suspended cells to settle under gravity into a monolayer at the bottom of the
389 reservoir. Microscopy was performed using an inverted microscope (Nikon Ti-E) and camera (QImaging,
390 Surrey, BC, Canada). A manual Z-scan through the fluid in the reservoirs was first performed to check for
391 unsettled cells. Next, tiled images of the waste and collection reservoirs were captured under both
392 green and blue fluorescence using an automated translating stage and then stitched into a composite
393 image (Microsoft Image Composite Editor). Finally, the UC13 cells in the waste and collection reservoirs,
394 as well as the number of leukocytes in the collection outlet are manually counted. Sample composite
395 images are shown in Supplemental Figure 1. Leukocytes in the waste outlet were too numerous to count
396 directly. Instead, their quantity was estimated from the total number of UC13 processed and the UC13-
397 leukocyte ratio in the original sample.

398 Measuring Cell Size

399 The size distribution of leukocytes and UC13 were determined by individually imaging at least 100 cells
400 from each phenotype underneath a cover-slip using a calibrated and manually focused 60X objective
401 lens. A watershed operation performed using ImageJ provided a measurement of cell area from which
402 cell diameter was estimated. While cells imaged under a coverslip are known to appear larger than their
403 true size in suspension [43], this technique is sufficient to assess the relative size of UC13 and leukocytes
404 since any distortion caused by the slip will apply to both phenotypes.

405 Cell Deformability Measurement

406 The deformability of the cell types used in cell separation studies was measured using a microfluidic
407 device developed previously by our group [22]. This device introduces single cells into a funnel shaped
408 constriction where the pressure required to push the cell through the constriction is measured
409 individually. To calibrate for differences in cell size, the cell is modeled as a liquid-filled sac where the
410 cortical tension of the membrane is readout as the intrinsic stiffness of the cell. Figure 5B report the
411 average and standard deviation of measurements of single cell cortical tension values, from at least 100
412 cells of each type.

413 Viability

414 The viability of captured cells was determined using a live/dead viability assay kit that tests cell
415 membrane integrity. Briefly, UC13 cells were incubated in a 2 μ M solution of calcein AM (Invitrogen)
416 and a 1 μ M solution of ethidium homodimer-1 (Invitrogen) for 30 minutes. The UC13 cells are then
417 processed using the resettable cell trap device and collected them in an outlet reservoir, where they
418 were counted using a fluorescence microscope. This process resulted in a decrease in viability of less
419 than 0.5%.

420 **References**

- [1] G. Vona et al., *Am J Pathol*, 2000, **156**, 1, 56-63.
- [2] S. H. Seal, *Cancer*, 1964, **17**, 5, 637-642.
- [3] C. G. Rao et al., *Int J Oncol*, 2005, **27**, 1, 49-57.
- [4] B. van der Gun et al., *Carcinogenesis*, 2010, **31**, 11, 1913-1921.

- [5] A. Chambers, A. Groom and I. MacDonald, *Nat Rev Cancer*, 2002, **2**, 563-572.
- [6] S. Cross, YS. Jin, J. Rao and J. Gimzewski, *Nature Nanotechnology*, 2007, **2**, 12, 780-783.
- [7] W. Xu et al., *PLOS ONE*, 2012, **7**, 10, e46609.
- [8] M. Yamada, M. Nakashima and M. Seki, *Anal Chem*, 2004, **76**, 5464-5471.
- [9] J. Davis et al., *Proc Natl Acad Sci USA*, 2006, **103**, 14779-14784.
- [10] V. VanDelinder and A. Groisman, *Anal Chem*, 2007, **79**, 2023-2030.
- [11] A. J. Mach, J. H. Kim, A. Arshi, SC. Hur and D. Di Carlo, *Lab Chip*, 2011, **11**, 17, 2827-2834.
- [12] S. Choi, S. Song, C. Choi and JK. Park, *Anal Chem*, 2009, **81**, 1964-1968.
- [13] F. Petersson, L. Aberg, AM. Sward-Nilsson and T. Laurell, *Anal Chem*, 2007, **79**, 5117-5123.
- [14] P. RC. Gascoyne, *Anal Chem*, 2009, **81**, 8878-8885.
- [15] J. Jung and KH. Han, *Appl Phys Lett*, 2008, **93**, 223902-223903.
- [16] KH. Han and A. B. Frazier, *Lab Chip*, 2008, **8**, 1079-1086.
- [17] D. Huh et al., *Anal Chem*, 2007, **79**, 4, 1369-1376.
- [18] X. Chen, D. F. Cui, C. C. Liu and H. Li, *Sens Actuators B Chem*, 2008, **130**, 216-221.
- [19] H. Mohamed, M. Murray, J. N. Turner and M. Caggana, *J Chromatogr A*, 2009, **1216**, 8289-8295.
- [20] S. Zheng et al., *Biomed Microdevices*, 2011, **13**, 203-213.
- [21] S. Zheng et al., *J Chromatogr A*, 2007, **1162**, 2, 154-161.
- [22] Q. Guo, S. Park and H. Ma, *Lab Chip*, 2012, **12**, 15, 2687-2695.
- [23] M. J. Rosenbluth, W. A. Lam and D. A. Fletcher, *Biophys J*, 2006, **90**, 2994-3003.

- [24] R. M. Hochmuth, *J Biomech*, 2000, **33**, 1, 15-22.
- [25] S. Quake, J. Marcus and C. Hansen, "Microfluidic Sieve Valves," 20080264863 A1, December 3, 2004.
- [26] SB. Huang, MH. Wu and GB. Lee, *Sensors and Actuators B*, 2009, **142**, 1, 389-399.
- [27] YH. Chang, CJ. Huang and GB. Lee, *Microfluid Nanofluid*, 2012, **12**, 1-4, 85-94.
- [28] KH. Nam and D. T. Eddington, *JMEMS*, 2010, **19**, 2, 375-383.
- [29] Q. Guo, S. Reiling, P. Rohrbach and H. Ma, *Lab on a Chip*, 2012, **12**, 1143-1140.
- [30] M. A. Unger, HP. Chou, T. Thorsen, A. Scherer and S. R. Quake, *Science*, 2000, **288**, 113-116.
- [31] Y. Xiang and D. A. LaVan, *Appl Phys Lett*, 2007, **90**, 13, 133901.
- [32] T. Gerhardt, S. Woo and H. Ma, *Lab Chip*, 2011, **11**, 231-2737.
- [33] L. Saias, J. Autebert, L. Malaquin and JL. Viovy, *Lab Chip*, 2011, **11**, 822-832.
- [34] A. Jain and L. L. Munn, *PLoS One*, 2009, **4**, 9, e7104.
- [35] S. Riethdorf et al., *Clin Cancer Res*, 2007, **13**, 920-928.
- [36] A. Makino et al., *Biorheology*, 2007, **44**, 221-249.
- [37] X. Chang and M. Gorbet, *Journal of Biomaterials Applications*, 2013, **28**, 3, 407-415.
- [38] S. M. McFaul, B. K. Lin and H. Ma, *Lab Chip*, 2012, **12**, 2369-2376.
- [39] S. S. Kuntaegowdanahalli, A. AS. Bhagat, G. Kumar and I. Papautsky, *Lab Chip*, 2009, **9**, 2973-2980.
- [40] SC. Hur, A. J. Mach and D. Di Carlo, *Biomicrofluidics*, 2011, **5**, 0222061-10.
- [41] M. Cristofanilli et al., *New England Journal of Medicine*, 2004, **351**, 8, 781-791.

[42] Z. Liu et al., *Journal of translational medicine*, 2011, **9**, 70,.

[43] G. W. Schmid-Schonbein, Y. Y. Shih and S. Chien, *Blood*, 1980, **56**, 866-875.